JMP Securities analyst Daniel Stauder has reiterated their neutral stance on AVNS stock, giving a Hold rating on February 26.
Daniel Stauder has given his Hold rating due to a combination of factors impacting Avanos Medical’s current and future performance. The company’s recent quarterly results showed a moderate beat in revenue and earnings, particularly in the Digestive Health segment. However, the guidance for 2025 indicates flat to slightly declining revenue and earnings, influenced by a challenging market environment and macroeconomic factors such as currency headwinds and tariffs.
Despite some positive developments like the divestiture of the respiratory health business and strong performance in the Trident U.S. market launch, Avanos is still in the midst of a transformational process. The company is working on refining its go-to-market strategy and organizational priorities, but there are still hurdles to achieving consistent progress. Given these uncertainties and the fair valuation of the stock, Stauder maintains a Hold rating, suggesting a wait-and-see approach as the company continues its reorganization efforts.
In another report released on February 26, Stifel Nicolaus also reiterated a Hold rating on the stock with a $17.00 price target.